导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.37% | 1850/4773 |
| 近一周 | -0.05% | 890/5465 |
| 近一月 | 5.04% | 69/5421 |
| 近一季 | 6.37% | 259/5231 |
| 近半年 | 5.59% | 786/4920 |
| 近一年 | 4.08% | 1926/4394 |
| 近两年 | 38.67% | 1960/2954 |
| 近三年 | 46.87% | 621/2253 |
| 成立以来 | 71.67% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.79% 2910/4961 |
-8.08% 3833/5312 |
- - |
- - |
| 2025 | 10.07% 2834/4813 |
2.51% 1351/3635 |
11.44% 184/4076 |
-8.58% 4050/4524 |
5.39% 448/4813 |
| 2024 | 38.71% 36/3463 |
9.97% 91/2808 |
6.77% 135/3014 |
12.48% 2334/3129 |
5.03% 651/3463 |
| 2023 | -2.82% 608/2656 |
-2.57% 2017/2280 |
2.07% 173/2385 |
4.64% 142/2515 |
-6.61% 1848/2655 |
| 2022 | -4.68% 101/2207 |
2.12% 79/1919 |
-1.46% 1725/2016 |
-8.22% 181/2113 |
3.21% 750/2208 |
| 2021 | 0.83% 704/1822 |
10.46% 39/1255 |
-1.55% 1172/1330 |
-6.84% 1000/1466 |
-0.48% 1242/1822 |
| 2020 | 4.32% 906/1250 |
-12.85% 902/1028 |
2.91% 957/1067 |
5.61% 904/1164 |
10.14% 614/1184 |
| 2019 | 31.81% 457/1092 |
15.77% 680/754 |
2.69% 73/804 |
2.85% 281/850 |
7.81% 395/918 |
| 2018 | -10.44% 70/834 |
- - |
- - |
- - |
-9.13% 129/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 南方中证银行ETF发起联接C VS. 长安沪深300非周期A(740101) |